Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples